LEADER 05221nam 2200625Ia 450 001 9910146099803321 005 20170809165237.0 010 $a1-282-02189-3 010 $a9786612021893 010 $a3-527-62597-6 010 $a3-527-62598-4 035 $a(CKB)1000000000724781 035 $a(EBL)481803 035 $a(OCoLC)476313717 035 $a(SSID)ssj0000262837 035 $a(PQKBManifestationID)11205118 035 $a(PQKBTitleCode)TC0000262837 035 $a(PQKBWorkID)10270942 035 $a(PQKB)11048707 035 $a(MiAaPQ)EBC481803 035 $a(PPN)19456987X 035 $a(EXLCZ)991000000000724781 100 $a20090520d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aTumor-associated antigens$b[electronic resource] $eidentification, characterization, and clinical applications /$fedited by Olivier Gires and Barbara Seliger 210 $aWeinheim $cWiley-VCH$dc2009 215 $a1 online resource (386 p.) 300 $aDescription based upon print version of record. 311 $a3-527-32084-9 320 $aIncludes bibliographical references and index. 327 $aTumor-Associated Antigens : Identification, Characterization, and Clinical Applications; Contents; List of Contributors; Part One Tumor-associated Antigens (TAAs): Subclasses of TAAs; 1 T Cell Antigens in Cancer; 1.1 Introduction; 1.2 Generation of T-cell Epitopes; 1.2.1 Subclasses of Tumor-associated T-cell Antigens; 1.2.1.1 Unique Tumor Antigens; 1.2.1.2 Cancer Testis Antigens; 1.2.1.3 Differentiation Antigens; 1.2.1.4 Overexpressed Antigens; 1.3 Identification of T-cell Antigens and their Epitopes; 1.3.1 T-cell Antigens for Cancer Immunotherapy - How are Candidates Selected? 327 $a1.4 ConclusionsReferences; 2 Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines; 2.1 Introduction; 2.2 Tumor Antigen Classes; 2.2.1 Oncofetal Antigens; 2.2.2 Oncogenes as Tumor Antigens; 2.2.3 Overexpressed Normal Molecules as Tumor Antigens; 2.2.4 Cancer-Testis (CT) Antigens; 2.2.5 Minor Histocompatibility Antigens (mHAgs) as Tumor Antigens; 2.2.6 Human Melanoma Antigens; 2.2.7 Human Glioma Antigens and Immunosurveillance in the CNS; 2.2.8 Heat Shock Proteins, Efficient Carriers of Tumor Antigens 327 $a2.2.9 Dendritic Cells, Efficient Cross-presenters of Tumor Antigens2.2.10 Spontaneous and Vaccine-induced Immunity and the Tumor Microenvironment; 2.3 Summary; References; Part Two Methods to Detect TAAs; 3 Humoral Immune Responses against Cancer Antigens: Serological Identification Methods. Part I: SEREX; 3.1 Introduction; 3.2 The SEREX Approach; 3.2.1 Identification of Human Tumor Antigens by SEREX; 3.2.2 Specificity of Human Tumor Antigens; 3.2.2.1 Shared Tumor Antigens; 3.2.2.2 Differentiation Antigens; 3.2.2.3 Antigens Encoded by Mutated Genes; 3.2.2.4 Viral Genes 327 $a3.2.2.5 Overexpressed Genes3.2.2.6 Amplified Genes; 3.2.2.7 Splice Variants of Known Genes; 3.2.2.8 Cancer-related Autoantigens; 3.2.2.9 Non-cancer-related Autoantigens; 3.2.2.10 Products of Underexpressed Genes; 3.2.3 Significance of Antibodies against SEREX Antigens; 3.2.4 Reverse T Cell Immunology; 3.2.5 Functional Significance of Human Tumor Antigens; 3.2.6 The Human Cancer Immunome; 3.2.7 Perspectives for Vaccine Development; 3.3 Conclusions; References; 4 Humoral Immune Responses against Cancer Antigens: Serological Identification Methods. Part II: Proteomex and AMIDA; 4.1 Introduction 327 $a4.1.1 A Humoral Response against Self-antigens: The Notion of Tumor-associated Antigens4.2 Implementation of Serum Antibodies: Serological Screening Technologies; 4.2.1 PROTEOMEX, alias SERPA and SPEARS; 4.2.1.1 PROTEOMEX Technology and its 'Pros' and 'Cons'; 4.2.1.2 Candidate Biomarkers Identified by PROTEOMEX; 4.2.1.3 Implementation of Candidate Biomarkers in the Clinic; 4.2.2 AMIDA; 4.2.2.1 Autologous AMIDA; 4.2.2.2 Allo-AMIDA; 4.2.3 Advantages and Disadvantages of AMIDA; 4.3 AMIDA Antigens and Clinical Application; 4.3.1 Diagnostic TAAs Detected with AMIDA Screening 327 $a4.3.2 Therapeutic Markers 330 $aThe first comprehensive and most recent overview of the topic, this ready reference and handbook reviews current knowledge of TAAs, their subclasses, and pinpoints their application areas in medicine. In addition, it emphasizes target identification procedures, the need for an accurate and thorough analysis of the function of TAAs, and the validation of those in clinical settings. The whole is rounded off with an overview of currently approved therapeutic antibodies.The result is a must-have for biologists and oncologists in science, clinics and industry. 606 $aTumor antigens 606 $aTumors$xImmunological aspects 615 0$aTumor antigens. 615 0$aTumors$xImmunological aspects. 676 $a616.994079 701 $aGires$b Olivier$0880096 701 $aSeliger$b Barbara$0880097 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910146099803321 996 $aTumor-associated antigens$91965167 997 $aUNINA LEADER 01781nam 2200433Ia 450 001 996390228103316 005 20221107141948.0 035 $a(CKB)1000000000651525 035 $a(EEBO)2240904443 035 $a(OCoLC)9920467500971 035 $a(EXLCZ)991000000000651525 100 $a19950918d1603 uy | 101 0 $aeng 135 $aurbn||||a|bb| 200 10$aBy the King$b[electronic resource] $ea proclamation against inmates and multitudes of dwellers in strait roomes and places in and about the cities of London, and for the rasing and pulling downe of certaine new erected buildings 210 $aImprinted at London $cBy Robert Barker, Printer to the Kings most Excellent Maiestie$dAnno Dom. 1603 215 $a1 sheet ([1] p.) 300 $aImperfect: cropped. 300 $a"Giuen at his Maiesties Mannor of Woodstocke, the sixteenth day of September, in the first yeere of our Raigne of England, France and Ireland, and of Scotland the seuen and thirtieth." 300 $aReproduction of original in: Society of Antiquaries. 330 $aeebo-0147 606 $aSlums$zEngland$zLondon 606 $aLodging-houses$zEngland$zLondon$vEarly works to 1800 606 $aHousing and health$zEngland$zLondon$vEarly works to 1800 606 $aPlague$zEngland$zLondon$xPrevention 607 $aGreat Britain$xHistory$yJames I, 1603-1625 608 $aBroadsides$zLondon (England)$y17th century.$2rbgenr 615 0$aSlums 615 0$aLodging-houses 615 0$aHousing and health 615 0$aPlague$xPrevention. 701 $aJames$cKing of England,$f1566-1625.$01001019 801 0$bEBK 801 1$bEBK 801 2$bWaOLN 906 $aBOOK 912 $a996390228103316 996 $aBy the King$92299281 997 $aUNISA LEADER 01937nam 22006014a 450 001 9910783423203321 005 20230617005038.0 010 $a1-282-15618-7 010 $a9786612156182 010 $a90-272-9389-9 035 $a(CKB)1000000000244075 035 $a(OCoLC)232157369 035 $a(CaPaEBR)ebrary10098697 035 $a(SSID)ssj0000206700 035 $a(PQKBManifestationID)11206838 035 $a(PQKBTitleCode)TC0000206700 035 $a(PQKBWorkID)10227405 035 $a(PQKB)10676896 035 $a(MiAaPQ)EBC622880 035 $a(Au-PeEL)EBL622880 035 $a(CaPaEBR)ebr10098697 035 $a(CaONFJC)MIL215618 035 $a(OCoLC)233650890 035 $a(EXLCZ)991000000000244075 100 $a20050623d2005 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aMultiple case narrative$b[electronic resource] $ea qualitative approach to studying multiple populations /$fAsher Shkedi 210 $aAmsterdam ;$aPhiladelphia $cJohn Benjamins Pub.$dc2005 215 $a1 online resource (227 p.) 225 1 $aStudies in narrative,$x1568-2706 ;$vv. 7 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a90-272-2647-4 320 $aIncludes bibliographical references p. (195-203) and index. 410 0$aStudies in narrative ;$vv. 7. 606 $aQualitative research$xMethodology 606 $aPopulation research$xMethodology 606 $aDiscourse analysis, Narrative 615 0$aQualitative research$xMethodology. 615 0$aPopulation research$xMethodology. 615 0$aDiscourse analysis, Narrative. 676 $a302/.072/3 700 $aShek?edi$b Asher$01538343 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910783423203321 996 $aMultiple case narrative$93788334 997 $aUNINA